Background: No previous prospective trials have been reported with capecitabine and gemcitabine (CAP-GEM) in patients with metastatic thymic epithelial tumors (TETs). We conducted a multicenter study to determine the activity and tolerability of this regimen in pretreated TETs.
introduction
Thymic epithelial tumors (thymoma and thymic carcinoma, TETs) are the most common tumors of anterior mediastinum in adults. Surgical resection of early-stage TET is a standard approach and >90% of patients with localized TETs are cured with complete surgical resection [1] . For patients with locally advanced disease, combination chemotherapy with additional local therapy (radiation therapy or surgery) is the treatment of choice. Systemic chemotherapy including cisplatin, doxorubicin and cyclophosphamide (PAC) is associated with a 50%-90% objective response rate (RR) [2, 3] but 50% of patients with locally advanced or metastatic TETs will be candidates for second-line therapy [1] . Several studies have documented 10%-30% of objective RRs with various drugs, such as ifosfamide, octreotide, fluorouracil and biological agents in recurrent TETs [1, 4, 5] .
Various studies, especially in gastrointestinal tumors, showed that capecitabine and gemcitabine (CAP-GEM) combination was active and well tolerated [6] [7] [8] [9] [10] .
To our knowledge, the effect of combining these agents in pretreated metastatic TETs is not known. We have evaluated the activity and safety of CAP-GEM for pretreated TET patients in a muticenter phase II clinical trial.
patients and methods patient selection
All patients were adults with histologically confirmed TET that was metastatic and measurable according to RECIST [11] .
All TETs were independently reviewed by a pathologist (MM).
Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of two or less; previous chemotherapeutic regimens, including platinum agent as first line; disease progression after previous treatment; hemoglobin >9 g/dl; absolute neutrophil count >1.5 ·
10
9 /l; platelets >100 · 10 9 /l; and normal renal, cardiac and liver functions. All patients gave informed consent for their treatment. The study complied with the provisions of the Declaration of Helsinki, Good Clinical Practice Guidelines and local laws.
study design
The study was an open-label, nonrandomized, Italian multicenter, phase II study approved by the institutional review boards at six participating centers. The primary end point was RR; secondary end points were safety, progression-free survival (PFS) and overall survival (OS).
Treatment consisted of oral capecitabine (650 mg/mq twice daily on days 1-14) and i.v. gemcitabine (1000 mg/mq on days 1 and 8) every 3 weeks (first cycle). In case of an objective partial response (PR) or stable disease (SD) (less than a 50% reduction and less than a 25% increase in the sum of the products of two perpendicular diameters of all measured lesions and the appearance of no new lesions), the patients could receive additional cycles until disease progression. Patients were seen on weeks 1 and 2 of each 3-week cycle; they had blood tests to check renal and hepatic functions and blood counts every week.
Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0) [12] . Grade 2 non-hematologic toxic effects were managed by holding the drug until resolution to £grade 1 and then resuming without a dose reduction. If the patient experienced a second grade 2 non-hematologic toxicity, the drugs was reduced by 25%. Grade 3 or 4 hematologic and non-hematologic toxic effects were managed through dose interruption, followed by 50% dose reduction. Treatment was discontinued if a grade 3 or 4 toxicity did not resolve within 3 weeks or if a second dose reduction was required.
assessment of tumor response
Tumor measurements were obtained by computed tomography scan, including the brain, before the treatment and for every three cycles. Response and progression were assessed by the treating physicians, who carried out their evaluations on the basis of RECIST [11] .
statistical design
For statistical considerations and study design, the primary end point was objective response. The RR was expected to be 25%; a total of 35 assessable patients were needed for a two-stage design with a type I error (alpha) of 0.05 and a type II error (beta) of 0.2. In the first stage, 15 patients were to be enrolled. If three or more responses were observed, the design called for an additional 20 eligible patients to be accrued.
We have decided to publish these interesting preliminary results of the first stage, and also if we have observed slow enrollment due to the rarity of those patients, we have planned to continue the trial to the second stage.
RR [complete response (CR) + PR] is reported with its exact 95% confidence interval (CI). Toxic effects are tabulated by type and grade. PFS was defined as the length of time during and after treatment in which a patient is living with a disease that does not get worse. OS was defined as the survival from registration until death. The 1-and 2-year survival rates were calculated from the date of registration to the 12th and 24th months.
Descriptive statistics were used to characterize patients at study entry. The Kaplan-Meier method was used to describe PFS and OS [13] . (Table 1) . Fourteen patients (93.3%) had an ECOG PS score of zero to one, while [14] , while the most common site of metastases was the pleura (100%). All patients had received at least two prior chemotherapeutic regimens, including cisplatin regimen, while eight patients (53.3%) had received three previous treatments. Median time between interruption of previous regimen and start of CAP-GEM was 5 weeks (range 3-12 weeks).
Most common paraneoplastic syndromes were lymphopenia, hypogammaglobulinemia and myasthenia gravis presented in 13, 11 and seven patients, respectively (Table 1) .
therapy administration
At total of 105 cycles were administered. The mean number of cycles per patient was 7 (median 6, range 3-9). The schedule resulted in a mean received dose intensity of 617.5 mg/mq twice, on days 1-14, for capecitabine; and 950 mg/mq, on days 1 and 8, for gemcitabine; or 95% of the planned dose intensity.
A dose reduction of 25% was adopted in six cycles (5.7%) due to grade 2 non-hematologic and hematologic toxicity. A dose reduction of 50% was adopted in six cycles (5.7%) due to grade 3 hematologic and non-hematologic toxic effects. Treatment was delayed in six cycles (5.7%). Reasons for delay were patient's request (four cycles) and investigator's decision (two cycles).
response and survival
All patients were included in analyses. Table 2 shows responses and survival rates in 15 patients. After six cycles, three patients each showed CR and PR (95% CI 10-35) for an overall RR of 40%. Six patients had SD for at least six cycles (40%). Figure 1 shows a CR in liver metastasis after six cycles.
Among three thymic carcinoma patients, we have observed one PR, one SD and one PD.
All six responder patients showed no change in paraneoplastic syndromes (stable B lymphopenia and hypogammaglobulinemia without increase of recurrent infections during chemotherapy and stable symptoms by myasthenia gravis).
Median follow-up was 22 months (range 8-28 months). Median PFS was 11 months (95% CI 3-17 months) (Figure 2) .
The PFS for patients with thymoma and thymic carcinoma was 11 months (95% CI 6-17 months) and 6 months (95% CI 3-11 months), respectively. The median survival time has not been reached for the patients to date. On the basis of Kaplan-Meier estimates, 1-and 2-year survival rates were 80% and 67%, respectively (Figure 3) . original article
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After disease progression with this regimen, 11 patients received only supportive care, while two patients each were treated with paclitaxel and docetaxel, respectively.
toxicity
In general, treatment was well tolerated. No toxic deaths occurred. Grade 1-2 nausea/vomiting, diarrhea, alopecia and hand-foot syndrome were the most common non-hematologic toxic effects, noted in four (26.7%), four (26.7%), three (20%), and three (20%) patients, respectively. The most important grade 3 hematologic toxicity was neutropenia in three patients (20%) and anemia in two patients (13%); grade 3 diarrhea was observed in one patient (6.7%). We did not observe grade 4 toxic effects (Table 3) . discussion Multiagent chemotherapy inclusive of cisplatin plays an important role in the treatment of advanced TETs [1] . A study conducted by the Southwest Oncology Group was designed to evaluate PAC in patients with advanced-stage disease. This combination yielded an overall RR of 50% and median survival was 38 months [2] . The combination of doxorubicin, cisplatin, vincristine and cyclophosphamide (ADOC) reported an overall RR of 92% and median survival of 15 months [3] .
Based on those results a chemotherapy regimen such as PAC or ADOC represents the standard first-line treatment in TETs.
Despite the high RR after first-line treatment, about 50%-70% will be candidates for second-line therapy [1, 4] .
To our knowledge, this study represents the first prospective investigation of CAP-GEM in TETs, both in first-line and in pretreated patients.
The preliminary findings show that CAP-GEM combination chemotherapy is active and well tolerated in pretreated TETs. The overall response rate (ORR) was 40% and an additional 40% of patients had SD.
It compares favorably with results previously reported for other combinations in pretreated patients, although it is impossible to directly compare the results.
It is also important to note that not many trials have been published in pretreated TETs with chemotherapy and the most active regimens, used in this setting, were octreotide and pemetrexed [15] [16] [17] .
Our group has previously conducted a study in 16 patients with advanced pretreated TETs with octreotide associated with prednisone. The overall RR was 37%. One patient had CR and five had PR [15] .
The octreotide activity was confirmed by an ECOG phase II that was conducted in patients with octreotide scan-positive TETs [16] . Out of 38 assessable patients, 32 had thymoma and 6 patients had thymic carcinoma or carcinoid; 82% had been exposed to prior chemotherapy. In the assessable patients, two CRs and 10 PRs were noted, yielding CR and PR rates of 5.3% and 25%, respectively. However, none of six patients with thymic carcinoma had objective response to therapy. Among those patients who received a combination of octreotide and prednisone, the ORR was noted higher at 31.6% but with increased toxicity [16] .
Compared with the Loehrer et al. study [16] , CAP-GEM combination appears more active (RR = 40%), also considering that our patients had received at least two prior regimens and were more pretreated than those in the previous study.
Results of the phase II study evaluating the role of pemetrexed in patients with recurrent TETs were reported in 2006 [17] .
In 23 assessable patients, two CRs and two PRs were noted. Median number of prior therapies was two. The median time to progression for patients with recurrent thymoma was 45.4 weeks and in patients with thymic carcinoma it was 5.1 weeks. If compared with those results, CAP-GEM combination shows higher response [17] .
Considering that no standard treatment exists in second line for TETs and as there limited options in this setting, the physicians have tried to use the biological agents in pretreated [19] .
Our group has previously published a case report with two patients who were treated with cetuximab. Both the patients reported a PR, suggesting that cetuximab may be a useful therapeutic choice in advanced TETs [20] .
In this scenario, CAP-GEM appears an attractive option in pretreated TETs.
Toxicity from treatment in our study was consistent with previous trials [8] [9] [10] . Grade 4 toxicity was not found and grade 2-3 toxicity was well controlled.
The study has several limitations. First, it is important to note that the responses in this study were investigator assessed and because independent review of scans can result in lowering of the RR relative to the investigator-assessed response, such an effect should be taken into consideration when interpreting the results.
Another limitation is that this was a nonrandomized study with limitations in determining the benefit of other agents such as cetuximab, bevacizumab or octreotide in second line.
It should be noted that our patients in some cases had received three previous regimens and could be useful to test this CAP-GEM in first line or second line.
Prospective randomized trials will be required to provide insight into the most effective option after disease progression with a cisplatin regimen.
Although our results are preliminary and limited by little number of enrolled patients, CAP-GEM combination appears active and well tolerated. Further clinical trials, also in first-line setting, are needed to confirm our important findings.
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